Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the fourteen research firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $13.60.
Several equities research analysts have weighed in on CMPX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Therapeutics in a report on Monday, April 20th. William Blair reiterated an “outperform” rating on shares of Compass Therapeutics in a report on Thursday, March 5th. Jefferies Financial Group reiterated a “buy” rating and issued a $9.00 target price on shares of Compass Therapeutics in a report on Thursday, March 5th. Raymond James Financial lowered shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, April 28th. Finally, Guggenheim restated a “buy” rating and set a $12.00 price objective on shares of Compass Therapeutics in a report on Tuesday, March 24th.
View Our Latest Stock Report on Compass Therapeutics
Compass Therapeutics Stock Performance
Compass Therapeutics (NASDAQ:CMPX – Get Free Report) last posted its earnings results on Tuesday, May 5th. The company reported ($0.10) earnings per share for the quarter, hitting the consensus estimate of ($0.10). Equities analysts forecast that Compass Therapeutics will post -0.44 EPS for the current fiscal year.
Institutional Investors Weigh In On Compass Therapeutics
Several institutional investors have recently added to or reduced their stakes in CMPX. Strs Ohio bought a new stake in Compass Therapeutics in the 1st quarter valued at $34,000. Creative Planning bought a new stake in Compass Therapeutics in the 2nd quarter valued at $30,000. XTX Topco Ltd bought a new stake in Compass Therapeutics in the 2nd quarter valued at $84,000. Invesco Ltd. lifted its position in Compass Therapeutics by 58.1% in the 2nd quarter. Invesco Ltd. now owns 58,735 shares of the company’s stock valued at $153,000 after acquiring an additional 21,578 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. lifted its position in Compass Therapeutics by 11.3% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,424,868 shares of the company’s stock valued at $11,505,000 after acquiring an additional 449,868 shares in the last quarter. 68.43% of the stock is owned by institutional investors.
About Compass Therapeutics
Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.
The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.
Read More
- Five stocks we like better than Compass Therapeutics
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for Compass Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
